HALIFAX, Feb. 4 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology
and solutions, today announced that the Company's Board of Directors
was elected at MedMira's 2011 Annual General and Special Meeting of
Shareholders, which was held on January 27th, 2011. Mr. Hermes Chan,
Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were
re-elected as directors of the Company.
"Under the guidance of our Board of Directors MedMira continues to push
forward with its strategic partnership strategy, working with partners
on a number of different aspects of the business including marketing
and business development, financing, and regional manufacturing hubs,"
said Hermes Chan, CEO, MedMira. "While MedMira and its partners are
experiencing extended sales cycles in some of its developing markets,
we do believe that the focus on strategic partnerships is the right
path for the Company's long term success. Initiatives are underway
with partners in most major markets around the world."
Dr. James Smith and Mr. Andre Archimbaud did not stand for re-election
and consequently ceased to be directors upon completion of the
Mr. Chan continued, "The Board thanks Dr. Smith and Mr. Archimbaud for
their service as directors."
Shareholders approved all other matters considered at the meeting
including the appointment of PricewaterhouseCoopers LLP as the
Company's auditors, ratification of the stock option plan, approval of
the year end financial statements, and the issuance of additional
shares through private placements over the coming year.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
infectious diseases in minutes. MedMira diagnostics are sold under the
Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets.
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MEDMIRA INC.
For further information:
MedMira Contact: Andrea Young